cobas® eplex respiratory pathogen panel 3

Fast, comprehensive results can help differentiate between SARS-CoV-2, influenza, RSV and other common respiratory pathogens



Coming soon!

The RP3 panel is built on the foundation of the RP2* panel with the same easy-to-use workflow, now with new targets and software features designed to improve your laboratory workflow and patient management.

Key features of the **cobas® eplex** RP3 panel

Easy-to-use workflow
Less than 1 minute of hands-on time enables on-demand testing on all shifts

Comprehensive coverage
Includes more than 20 of the most common viral and bacterial pathogens causing respiratory illness

Fast results for high risk patients
Enables clinicians to make patient management decisions in a clinically actionable timeframe

Compatible with unique software features of the cobas eplex system
- Templated comments
- Bi-directional LIS connectivity
- QC tracking and flexible syndromic testing features simplify lab workflow and streamline result reporting

Simple workflow: Less than 1 minute of hands-on time



Load sample → Scan cartridge → Insert cartridge

The clinical presentation of respiratory pathogens is similar, complicating diagnosis and therapy selection. Fast, accurate results are critical, especially in high risk patients.

Severe respiratory infections can lead to hospitalisation or death

While most infections are mild, complications such as pneumonia or sepsis can occur.[1]

People at high risk for complications[1-3]



Pregnant women



Children < 2 and adults 65+



Anyone with a compromised immune system

Medical conditions that increase risk

- Stroke
- Asthma
- Diabetes
- Weakened immune system
- Blood, lung, heart, kidney and liver disease

Comprehensive coverage of the most common respiratory pathogens

Viral targets

Adenovirus
Enterovirus/rhinovirus
Coronavirus 229E‡
Coronavirus HKU1‡
Coronavirus NL63‡
Coronavirus OC43‡
SARS-CoV-2
Human metapneumovirus
Human parainfluenza virus 1
Human parainfluenza virus 2
Human parainfluenza virus 3
Human parainfluenza virus 4
Influenza A virus
Influenza A virus H1
Influenza A virus H1-2009
Influenza A virus H3
Influenza B virus
RSV A
RSV B

Bacterial targets

Bordetella pertussis†
Chlamydia pneumoniae
Mycoplasma pneumoniae

† New target on the cobas eplex RP3 panel (US). This information reflects design goals and is subject to change.
‡ In the US, a combined result of human coronavirus is reported.

*cobas eplex RP2 has not been FDA approved/cleared but has been authorized for use under an EUA for authorized labs.

cobas® eplex respiratory pathogen panel 3

Key parameters	Description
Platform	**cobas® eplex** system
Sample type	Nasopharyngeal swab (NPS)
Sample volume	200 µL
Test duration	< 2 hours
Kit size	12 tests

References

1 ECDC urges immunisation and other measures as Europe enters respiratory virus season. European Centre for Prevention and Disease Control. https://www.ecdc.europa.eu/en/news-events/ecdc-urges-immunisation-and-other-measures-europe-enters-respiratory-virus-season. Date accessed: September 2026.

2 Respiratory syncytial virus (RSV). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/respiratory-syncytial-virus-(rsv). Date accessed: September 2026.

3 Influenza (seasonal). World Health Organization. https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal). Date accessed: September 2026.

For *In Vitro* Diagnostic Use.
US: Pending 510(k) clearance. This information reflects design goals and is subject to change. Not available for sale in the US.

COBAS and EPLEX are trademarks of Roche.
©2026 F. Hoffmann-La Roche Ltd

MC-US-19602 Rev. 1 09/2026

diagnostics.roche.com/eplex